Darbepoetin alpha is highly cost-effective compared with epoetin alpha in the treatment of renal anemia: a brief report from a hemodialysis clinic in Japan.
Nakagawa
Tetsuya
T
D000740:Anemia / Q000188:drug therapy / Q000191:economics / Q000209:etiology; D003362:Cost-Benefit Analysis; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000191:economics* / Q000627:therapeutic use; D006397:Hematinics / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D007564:Japan; D011994:Recombinant Proteins; D006435:Renal Dialysis
D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa